{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C%2C+Genotype+1&page=2", "query": { "condition": "Hepatitis C, Genotype 1", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C%2C+Genotype+1&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T04:23:41.083Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00077649", "title": "A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "ribavirin [Copegus]", "type": "DRUG" }, { "name": "peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 188, "start_date": "2004-01", "completion_date": "2005-12", "has_results": true, "last_update_posted_date": "2016-04-18", "last_synced_at": "2026-07-24T04:23:41.083Z", "location_count": 24, "location_summary": "La Jolla, California • Long Beach, California • San Diego, California + 20 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Farmington", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077649" }, { "nct_id": "NCT00559247", "title": "A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "BMS-650032 or Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 24, "start_date": "2008-01", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2010-09-13", "last_synced_at": "2026-07-24T04:23:41.083Z", "location_count": 5, "location_summary": "Cypress, California • Orlando, Florida • Baltimore, Maryland + 2 more", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00559247" }, { "nct_id": "NCT01157975", "title": "Study the Relationship Between Obesity and Hepatitis C Replication", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Pioglitazone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2008-10", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2019-12-02", "last_synced_at": "2026-07-24T04:23:41.083Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01157975" }, { "nct_id": "NCT01194037", "title": "A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Hepatitis C Infection", "Genotype 1" ], "interventions": [ { "name": "recombinant variant of interferon-alpha 2b", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HanAll BioPharma Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2011-06-23", "completion_date": "2011-11-28", "has_results": false, "last_update_posted_date": "2025-04-22", "last_synced_at": "2026-07-24T04:23:41.083Z", "location_count": 6, "location_summary": "Los Angeles, California • National City, California • Miami, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01194037" }, { "nct_id": "NCT01573351", "title": "Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Asunaprevir", "type": "DRUG" }, { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Peg-interferon Alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 398, "start_date": "2012-05", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-07-24T04:23:41.083Z", "location_count": 20, "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 16 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01573351" }, { "nct_id": "NCT01290679", "title": "An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "TMC435", "type": "DRUG" }, { "name": "Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 393, "start_date": "2011-03", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2014-06-13", "last_synced_at": "2026-07-24T04:23:41.083Z", "location_count": 11, "location_summary": "Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Crestview Hills", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01290679" }, { "nct_id": "NCT01628094", "title": "ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "RO5024048", "type": "DRUG" }, { "name": "RO5190591", "type": "DRUG" }, { "name": "RO5466731", "type": "DRUG" }, { "name": "ribavirin [Copegus]", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2012-06", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-07-24T04:23:41.083Z", "location_count": 15, "location_summary": "La Jolla, California • Englewood, Colorado • South Miami, Florida + 11 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "South Miami", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01628094" }, { "nct_id": "NCT00274495", "title": "Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Hepatitis C Infection", "Fatty Liver" ], "interventions": [ { "name": "Rosiglitazone and Pegasys/Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2006-01", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2007-11-01", "last_synced_at": "2026-07-24T04:23:41.083Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00274495" }, { "nct_id": "NCT01405027", "title": "Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Hepatitis C", "Genotype 1" ], "interventions": [ { "name": "Educational Intervention", "type": "PROCEDURE" }, { "name": "Patient education and management skills training", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Chronic Liver Disease Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 197, "start_date": "2011-12", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2015-01-06", "last_synced_at": "2026-07-24T04:23:41.083Z", "location_count": 43, "location_summary": "Beverly Hills, California • Calabasas, California • Santa Monica, California + 34 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Calabasas", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01405027" }, { "nct_id": "NCT01281839", "title": "An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "TMC435", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Peginterferon alpha-2a (PegIFN alpha-2a)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 394, "start_date": "2011-02", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2014-04-23", "last_synced_at": "2026-07-24T04:23:41.083Z", "location_count": 11, "location_summary": "Bakersfield, California • Aurora, Colorado • Jacksonville, Florida + 8 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01281839" } ] }